-
Mashup Score: 1Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis - 1 month(s) ago
Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. | Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. The cell therapy developer blamed imbalances between cohorts for the mixed results—and contended the effect on a small subgroup of sepsis patients suggests the candidate has a future.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 21AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech - 1 month(s) ago
A session at the American Association for Cancer Research (AACR) annual meeting posed a key question: Are cancer vaccines ready for prime time? | A session at the American Association for Cancer Research annual meeting asked a key question: Are cancer vaccines ready for prime time? If you ask Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, the answer is a quick yes.
Source: www.fiercebiotech.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2BrainStorm, plotting Lazerus-like recovery, aligns with FDA on design of phase 3b ALS trial - 1 month(s) ago
BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis (ALS). | BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis. A piece of the latest comeback strategy slotted into place Tuesday when the biotech revealed a written agreement with the FDA on the design of a phase 3b trial.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 12
Roche raised the curtain on its upcoming continuous glucose monitoring system featuring artificial intelligence-powered forecasts of blood sugar highs and lows. | At the International Conference on Advanced Technologies and Treatments for Diabetes, being held this week in Florence, Italy, the company put forward the first accuracy data for its new Accu-Chek SmartGuide sensor and apps.
Source: www.fiercebiotech.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2
CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S. | CureVac and GSK have been racing behind Moderna to try and get the first mRNA flu vaccine to market. But now the European partners have come up against the exact same problem as their U.S. competitor when it comes to the “historically challenging” B strains of influenza.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0ProJenX ALS treatment gets back on the map after partial FDA hold - 2 month(s) ago
ProJenX is back on the map after the FDA lifted a partial clinical hold on a phase 1 clinical trial for an amyotrophic lateral sclerosis (ALS) drug. | ProJenX is back on the map after the FDA lifted a partial clinical hold on a phase 1 clinical trial for an amyotrophic lateral sclerosis drug.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 2Moderna's early vaccine pipeline underpinned by Epstein–Barr, norovirus and shingles prospects - 2 month(s) ago
Moderna’s COVID-19 vaccine was a blockbuster. Highly anticipated shots protecting against respiratory syncytial virus and cytomegalovirus are on deck. | Moderna gave its clearest look yet at a third wave of vaccine products during the company’s annual vaccines business review on Wednesday. Early-stage shots aimed at Epstein–Barr virus, norovirus and shingles could further solidify the biotech’s infectious disease portfolio.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans - 2 month(s) ago
Altimmune has been beaten by hepatitis B. | Altimmune has been beaten by hepatitis B. The drug candidate, which Altimmune was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech to stop development and focus on its GLP-1/glucagon dual receptor agonist.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.” | Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.”
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Brii goes all in on HPV, punting HIV, depression, lung disease programs to potential partners - 2 month(s) ago
Brii Biosciences is
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
“Enlivex takes cells from healthy donors and makes them express an “eat me” signal. After administration, macrophages duly eat the cells and homeostasis is restored.” https://t.co/xLkPV0V1Ow